Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.

Autor:	Umutlu L; Department of Diagnostic and Interventional Radiology and Neuroradiology, University-Hospital Essen, Germany., Beyer T; QIMP Group, Centre for Medical Imaging and Biomedical Engineering, Medical University of Vienna, Austria., Grueneisen JS; Department of Diagnostic and Interventional Radiology and Neuroradiology, University-Hospital Essen, Germany., Rischpler C; Department of Nuclear Medicine, University-Hospital Essen, Germany., Quick HH; High-Field- and Hybrid-MR-Imaging, University-Hospital Essen, Germany., Veit-Haibach P; Joint Department of Medical Imaging, University of Toronto, Canada., Eiber M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany., Purz S; Department of Nuclear Medicine, University of Leipzig, Germany., Antoch G; Department of Diagnostic and Interventional Radiology, University Düsseldorf, Medical Faculty, Düsseldorf, Germany., Gatidis S; Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany., Nikolaou K; Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany., Schaefer JF; Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany., Rausch I; QIMP Group, Centre for Medical Imaging and Biomedical Engineering, Medical University of Vienna, Austria., Herrmann K; Department of Nuclear Medicine, University-Hospital Essen, Germany.
Jazyk:	angličtina
Zdroj:	RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin [Rofo] 2019 Apr; Vol. 191 (4), pp. 289-297. Date of Electronic Publication: 2019 Feb 28.
DOI:	10.1055/a-0828-8654
Abstrakt:	Combined PET/MR imaging (PET/MRI) was proposed for patient management in 2006 with first commercial versions of integrated whole-body systems becoming available as of 2010. PET/MRI followed the prior evolution of hybrid imaging as attested by the successful adoption of combined PET/CT and SPECT/CT since the early 2000 s. Today, around 150 whole-body PET/MRI systems have become operational worldwide. One of the main application fields of PET/MRI is oncologic imaging. Despite the increasing use of PET/MRI, little governance regarding standardized PET/MRI protocols has been provided to date. Standardization and harmonization of imaging protocols is, however, mandatory for efficient on-site patient management and multi-center studies. This document summarizes consensus recommendations on key aspects of patient referral and preparation, PET/MRI workflow and imaging protocols, as well as reporting strategies for whole-body [18F]-FDG-PET/MRI. These recommendations were created by early adopters and key experts in the field of PET, MRI and PET/MRI. This document is intended to provide guidance for the harmonization and standardization of PET/MRI today and to support wider clinical adoption of this imaging modality for the benefit of patients. CITATION FORMAT: · Umutlu L, Beyer T, Grueneisen JS et al. Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. Fortschr Röntgenstr 2019; 191: 289 - 297. Competing Interests: Dr. Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, outside the submitted work.The other authors declare that they have no conflict of interest. (© Georg Thieme Verlag KG Stuttgart · New York.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu